Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

combination

combination is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 277
News articles 0
Drug details — combination
Class
—
Route
—
Patents
20
Programs
277
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

combination is an FDA-listed pharmaceutical active ingredient.

Key facts

INN combination

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 67652000PCR3002 Phase 3 · Janssen-Cilag International N.V · Deleterious Germline or Somatic Homologous Recombination Rep
  2. ADAURA - D5164C00001 Phase 3 · AstraZeneca · Stage IB-IIIA non-small cell lung carcinoma, with a centrall
  3. APHP200026 Phase 3 · PARItec · Patients with GPA and inadequate response to standard of car
  4. AT-01B-008 Phase 3 · Atea Pharmaceuticals · Chronic Hepatitis C Virus (HCV) Infection
  5. Aceclidine+Brimonidine combination ophthalmic solution Phase 3 · LENZ Therapeutics · Presbyopia
  6. Aclidinium bromide/formoterol Fixed-Dose Combination Phase 3 · AstraZeneca · COPD
  7. Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) Phase 3 · AstraZeneca · Chronic Obstructive Pulmonary Disease
  8. BN42644 Phase 3 · HOFFMANN-LA ROCHE · Spinal Muscular Atrophy (SMA)

Related patents

Browse patents

  1. PT 3886798

    COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF

    Expires Wed Apr 11 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 20260097057

    COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS

    Expires Wed Apr 04 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 2025388678

    Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

    Expires Wed Dec 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12414934

    Combination therapies

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12409167

    Pharmaceutical combination comprising a selective S1P1 receptor agonist

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12404318

    Combination HBV therapy

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12377115

    Combination immunotherapies for treatment of cancer

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12377101

    Combination therapies

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CN 120418289

    Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

    Expires Thu Jul 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12370232

    Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12351581

    Compounds for FGFR inhibition

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12350318

    Combination therapy to treat brain cancer

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12336995

    Combination therapies

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12319738

    Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12281173

    Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12280055

    Combination therapies

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12268694

    Combination pharmaceutical agents as RSV inhibitors

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is combination?

combination is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.